healthcare.digital August 4, 2025
Nelson Advisors partners Lloyd Price and Paul Hemings interviewed by Mergermarket for their ‘AI fuels European medtech M&A despite regulatory uncertainty’ story.
https://mergermarket.ionanalytics.com/content/1004331406?source=news
‘AI fuels European medtech M&A despite regulatory uncertainty’
Europe’s medtech M&A activity is making a comeback as buyers clamour for artificial intelligence (AI) assets amid regulatory fragmentation and uncertainty.
“With AI as the enabler, there’s a feeling companies don’t want to get left behind. You can’t sit on your laurels,” Lloyd Price, partner at the European healthtech M&A advisor Nelson Advisors, told Mergermarket.
One crucial consideration is the EU’s recent Medical Device Regulation and In Vitro Diagnostic Regulation, Paul Hemings, also partner at NelsonAdvisors, said. These measures have tightened requirements for clinical evidence, documentation, and post-market surveillance...
Today's Sponsors
Today's Sponsor